News

Survey results paint portrait of trends, technology’s effect on cataract practice

Lens demonstrated excellent rotational stability, visual outcomes in clinical trials

Corneal inlay allows presbyopia correction either paired with or after LASIK

Ian MacDonald, MSc, MD, talked about the future of gene therapy trials in choroideremia, a single-gene disorder that primarily affects the eye.

Cosmetic eyelash extensions and the adhesives used to apply them to eyelids can present dangers to consumers.

Ophthalmologists Leonard Flom, MD, and Aran Safir, MD, have been inducted into the National Inventors Hall of Fame for the invention of the iris recognition scanner.

Allegro Ophthalmics LLC and Senju Pharmaceutical Co. Ltd. have entered into a collaboration and agreement to develop and market Allegro’s integrin peptide therapy in Japan.

Once-daily dosing delivers rapid, potent control of postoperative pain, inflammation

Chemical enhancements to riboflavin solution aim to overcome need for epithelial debridement

Algorithm helps ophthalmologists decide best treatment option for patients based on data

Today’s options for patients with low vision go beyond traditional vision aids

Historical perspective captures transition from traditional to modern medicine

On the art of recommending eyeglasses to patients during the examination

Supplementation will keep the vitamin A levels above the critical threshold

Wound construction, IOL calculations, lens selection among variables in special population

On the rippling effects of alleviating suffering for free

Some older and newer treatments being studied for treating uveitis include iontophoresis, contact lenses, and nanoparticles.

Stephen J. Ryan, MD, a member of the Allergan Board of Directors, died on April 29, 2013 after a short illness.

A new PDUFA goal date has been established with the FDA for Iluvien fluocinolone acetonide implant (Alimera Sciences Inc.), and a PAS has been submitted to NICE in the United Kingdom.

EGP-437 (EyeGate Pharma), a corticosteroid formulation, was found to match the response rate to prednisolone acetate 1% for treatment of anterior uveitis.

New data show that a retinal prosthesis system is capable of providing face detection functionality to blind individuals, said Paulo E. Stanga, MD.

A new compound shows potential as a novel targeted therapy for retinoblastoma. While studies are still in the preliminary stages, the compound known as sd-rxRNA was able to penetrate all cell layers of the retina and was taken up by tumor cells within 24 hours of intravitreal administration, said Michael Byrne, PhD.

Symptomatic floaters can be safely and effectively treated with vitrectomy using 25-gauge instruments, and without inducing posterior vitreous detachment or removing the anterior vitreous, said Christianne A. Wa, a third-year medical student at USC School of Medicine, Los Angeles.

An estimated 25 million people in the United States have diabetes and face a higher risk for ophthalmic complications, including glaucoma, cataracts, and diabetic retinopathy. However, more than one-third of all persons in the United States with diabetes did not undergo an eye exam in the past year, said Fang Ko, MD.

One of the most unique aspects of the Association for Research in Vision and Ophthalmology (ARVO) meeting that ophthalmic clinicians won't find at any other meeting-including the American Academy of Ophthalmology (AAO) and American Society of Refractive and Cataract Surgery (ASCRS) meetings-is the poster sessions.

Pseudoexfoliation syndrome (PEX) appears to be significantly associated with both cardiovascular (CVD) and cerebrovascular disease (CVA), according to a new meta-analysis, said Helen Chung, MD.

The cost of caring for patients with glaucoma has risen in the past decade, but at a lower rate than that of general or medical inflation. For Medicare beneficiaries, the greatest expense was not the treatment for glaucoma per se, but rather for cataracts and retinal eye care, said Harry Quigley, MD.

As of Tuesday afternoon at this year's Association for Research in Vision and Ophthalmology (ARVO) meeting, all of the head-to-head comparison studies involving the efficacy and the safety of ranibizumab (Lucentis) and bevacizumab (Avastin) are officially IN.